What is the er - pr ihc cancer screening test?

The ER-PR IHC cancer screening test is a laboratory test that is used to identify the presence of estrogen receptor (ER) and progesterone receptor (PR) in cancer cells. This test helps doctors determine the type of breast cancer a person has, as well as the best treatment options for the specific type of cancer. The test is performed on a tissue sample obtained from a biopsy, and the results are reported as positive or negative for ER and PR expression. Positive results indicate that the cancer cells have receptors for these hormones, which can be treated with hormone therapy. Negative results suggest that hormone therapy may not be effective in treating the cancer. The ER-PR IHC cancer screening test is an important tool in the diagnosis and treatment of breast cancer.

What is the purpose of the er - pr ihc cancer screening test?

The ER-PR IHC cancer screening test is used to determine the presence or absence of estrogen and progesterone receptors in cancer cells. The purpose of this test is to help doctors determine the most effective treatment for breast cancer patients. This is because cancer cells that have estrogen and progesterone receptors are more likely to respond to hormone therapy, which can slow or stop the growth of cancer cells. Therefore, the ER-PR IHC cancer screening test is an important tool in identifying the most appropriate treatment plan for breast cancer patients.

How is the er - pr ihc cancer screening test administered?

The ER-PR IHC cancer screening test is administered through a biopsy of the suspected cancerous tissue. A small sample of the tissue is taken and sent to a laboratory where it is analyzed for the presence of estrogen receptor (ER) and progesterone receptor (PR) proteins using immunohistochemistry (IHC) staining. The test results help doctors determine the best course of treatment for the patient based on the hormone receptor status of the cancer cells. This type of screening is commonly used in breast cancer diagnosis and treatment. It is a minimally invasive procedure and can be performed on an outpatient basis.

What types of cancer can be detected through the er - pr ihc cancer screening test?

The ER-PR IHC cancer screening test is used to detect certain types of breast cancer. The test checks for the presence of estrogen receptors (ER) and progesterone receptors (PR) in the breast tissue. Breast cancer that is positive for these receptors tends to respond well to hormone therapy, making early detection crucial for successful treatment. However, it is important to note that not all breast cancers are ER-PR positive, and other tests may be necessary to diagnose different types of cancer.

Are there any special preparations required before taking the er - pr ihc cancer screening test?

Yes, there are some special preparations that might be required before taking the ER-PR IHC cancer screening test. It is recommended to consult with your healthcare provider regarding specific instructions, as they may vary depending on the type of tissue sample being collected.

In general, the preparation for the ER-PR IHC test may involve avoiding certain medications or supplements that could interfere with the results. Your doctor may also advise you to avoid certain foods or drinks for a specific period before the test.

Additionally, you may need to provide a tissue sample for the test, which may be collected through a biopsy or surgery. Before the procedure, your doctor may provide specific instructions on how to prepare for the tissue collection, such as fasting or stopping certain medications.

Overall, it is important to follow your doctor's instructions carefully to ensure accurate and reliable test results. Remember to inform your healthcare provider about any medications, supplements, or health conditions you have before the test to avoid any potential complications.

Description

• Prognostic for breast cancer
• Predictive for response of breast cancers and endometrial cancers to hormonal therapy
• Differentiates
• endocervical
• from endometrial adenocarcinomas

Methodology: Immunohistochemistry

TAT: 3-5 days

Specimen Preparation

• Collect - tissue /or cell
• Specimen Preparation- formal fix (10 % neutral buffered formalin) and paraffin enter specimen (FFPE specimens square measure needed). shield paraffin block or slides from uncontrolled heat. Transport tissue block or five unstained (3-micron thick sections), charged slides during a tissue transport kit. (Min: a pair of slides). If causing precut slides, don't over heat it.
• Storage/Transport Temperature- At temperature or cold. Transport it in cooled instrumentation throughout weather.
• Unacceptable conditions-
  • Specimens submitted with non-marked/tagged tissue sort square measure rejected.
  • Depleted specimens aren't tested.
• Stability-
  • Ambient: Indefinitely;
  • Refrigerated: Indefinitely;
  • Frozen: Unacceptable